TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07660341: A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Ascending Doses of CGB3002 in Healthy Participants

Sponsor: ChainGen Biopharma Ltd · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT07660341 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07660341 Rescue Dossier →